ExCellThera

Growing blood stem cells for therapeutic use

4 undisclosed programs Clin0 organ transplant, undisclosed

ExCellThera is developing stem cell therapies to engineer various cell lines for hematological malignancies. Thousands of patients in need of stem cell transplants are in need of a donor and those that do get one, do not always respond. ExCellThera is addressing this problem through the development of novel, one-time curative cell therapies based on their proprietary UM171 technology. UM171 is a molecule with hematopoeitic stem cell expansion properties which can be used to expand the low number of stem cells found in cord blood. ExCellThera’s lead candidate cell therapy, ECT-001, is composed of UM171-expanded stem cells to treat blood diseases. Initial Phase I/II clinical trials have already been completed with promising results.

Jobs: